IDH-305
Cat. No.: DC10538
Featured
Chemical Structure
1628805-46-8
We are official vendor of:
More than 5000 active chemicals with high quality for research!
Field of application
IDH305 is an inhibitor of the citric acid cycle enzyme isocitrate dehydrogenase [NADP] cytoplasmic (isocitrate dehydrogenase 1; IDH1) with mutations at residue R132 (IDH1(R132)), with potential antineoplastic activity.
| Cas No.: |
1628805-46-8 |
| Chemical Name: |
(4R)-4-[(1S)-1-fluoroethyl]-3-(2-{[(1S)-1-[4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl]ethyl]amino}pyrimidin-4-yl)-1,3-oxazolidin-2-one |
| Synonyms: |
IDH-305 |
| SMILES: |
O=C1OC[C@H]([C@@H](F)C)N1C2=NC(N[C@H](C3=CC(C)=C(C4=CC(C(F)(F)F)=NC=C4)C=N3)C)=NC=C2 |
| Formula: |
C23N6O2F4H22 |
| M.Wt: |
490.4534 |
| Purity: |
>98% |
| Sotrage: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: |
IDH-305 is an inhibitor of isocitrate dehydrogenase (IDH). |
| In Vitro: |
IDH-305 is an inhibitor of isocitrate dehydrogenase (IDH). Isocitrate dehydrogenase (IDH) is an essential enzyme for cellular respiration in the tricarboxylic acid (TCA) cycle. The IDH1 inhibitor IDH-305 has entered an ongoing phase 1 clinical trial (NCT02381886) for patients with IDH1-R132 mutant advanced hematologic or solid malignancies[1]. |
| References: |
[1]. Fujii T,et al. Targeting isocitrate dehydrogenase (IDH) in cancer. Discov Med. 2016 May;21(117):373-80. |
MSDS
COA
| LOT NO. |
DOWNLOAD |
|
|
| 2018-0101 |
|
| 2018-0101 |
|
Get Quote
